Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment

A. Bianco, A. K. Patanella, Viviana Nociti, Chiara De Fino, Matteo Lucchini, Francesco Lo Savio, Paolo Maria Rossini, Massimiliano Mirabella

Research output: Contribution to journalArticlepeer-review

Abstract

In phase II clinical trial, fingolimod at a dose of 5.0 mg (ten times higher than the currently approved dose) induced dyspnoea and decreased forced expiratory flow in some patients, probably trought an airways constriction S1P4-mediated. In phase III trials, respiratory adverse events associated with fingolimod treatment as dyspnoea, cough, oropharingeal pain and nasal congestion are reported with the same incidence of placebo. Here we report two cases of severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment, which led to permanent treatment withdrawal.

Original languageEnglish
Pages (from-to)11-13
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume9
DOIs
Publication statusPublished - Sep 1 2016

Keywords

  • Adverse event
  • Fingolimod
  • Multiple sclerosis
  • Respiratory
  • Side effect

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment'. Together they form a unique fingerprint.

Cite this